Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases
STTK•Pipeline, safety and cash position
Phase 1 program in healthy participants completed; SL-325 reported a 3.7% anti-drug antibody rate; estimated half-life is 16 days.
Preclinical pipeline includes SL-846, a DR3 x IL-23 receptor antibody with Phase 1 initiation expected in 1H 2027.
Cash and equivalents and short-term investments totaled $208.3 million as of June 30, 2026; runway is expected into 2029.
Investor deck highlights SL-325 and inflammatory disease strategy
Shattuck Labs outlined a strategy to develop potentially first-in-class DR3-blocking antibodies for inflammatory and immune-mediated diseases, led by SL-325.
The RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn’s disease is expected to start in Q3 2026; 12-week induction data are targeted for 1H 2028.
